VC  VenBio

     Office Locations:

360 University Avenue
Palo Alto, CA 94301
Phone: +1 415-800-0800

Get all office locations for this firm with a National Database subscription or Silicon Valley Database subscription.


  • Early
  • Expansion
  • Growth



  • Life Sciences & Healthcare



    venBio is a life sciences investment firm, partnering with industry leaders to build and invest in game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. With a presence in San Francisco, CA, venBio manages both a long/ short equity strategy along with venture capital funds which are backed by leading life sciences companies and qualified financial investors. The two venBio strategic funds have invested in 14 companies to date, including: Cytos (now KURN), Aragon (acquired by J&J), Solstice, Labrys (acquired by Teva), Seragon (acquired by Roche/Genentech), Aurinia (AUPH), Heart Metabolics, Metacrine, Alexo, Precision Biosciences, Checkmate, Adheren, Apellis, and Nabriva (NBRV). In May 2016, the firm closed venBio Global Strategic Fund II, its second life sciences venture capital fund, for a total of approximately $315 million, exceeding its target of $250 million. venBio's Strategic Fund II is anchored by major investments from three strategic limited partners - Amgen, Merck, and Baxalta -along with a group of financial Limited Partners. The firm announced (April 2020) the closing of venBio Global Strategic Fund III, its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in capital commitments in an oversubscribed fundraise.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Aaron Royston MD, MBA Managing Partner
    Corey Goodman PhD Managing Partner
    David Pezeshki CFA, CPA CFO
    Jaume Pons PhD Venture Partner
    Richard Gaster MD, PhD Managing Partner


    Recent Funding Events (trailing 12 months):










      Series A





      Series D





      Series C


    Portfolio companies include:


    Recent News: